Compare Stocks: UNCY, TLRY, OVID, and CTNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$16.02 +10.5%	$14.29	$8.54 ▼ $16.91	$545.51M	0.74	487,481 shs	545,502 shs
OVID Ovid Therapeutics	$2.93 +3.2%	$2.51	$0.89 ▼ $3.11	$554.65M	0.21	1.55 million shs	2.88 million shs
TLRY Tilray Brands	$4.83 +8.1%	$4.49	$3.67 ▼ $23.20	$608.83M	1.9	4.90 million shs	5.60 million shs
UNCY Unicycive Therapeutics	$5.58 -0.9%	$5.84	$3.71 ▼ $8.74	$156.82M	1.79	767,239 shs	845,887 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+10.48%	+6.94%	+18.40%	+11.48%	+72.26%
OVID Ovid Therapeutics	+3.17%	+11.83%	+26.84%	+20.08%	+211.70%
TLRY Tilray Brands	+8.05%	+3.21%	+14.18%	-11.54%	-54.43%
UNCY Unicycive Therapeutics	-0.89%	+3.53%	+2.39%	-26.87%	+37.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$16.02 +10.5%	$14.29	$8.54 ▼ $16.91	$545.51M	0.74	487,481 shs	545,502 shs
OVID Ovid Therapeutics	$2.93 +3.2%	$2.51	$0.89 ▼ $3.11	$554.65M	0.21	1.55 million shs	2.88 million shs
TLRY Tilray Brands	$4.83 +8.1%	$4.49	$3.67 ▼ $23.20	$608.83M	1.9	4.90 million shs	5.60 million shs
UNCY Unicycive Therapeutics	$5.58 -0.9%	$5.84	$3.71 ▼ $8.74	$156.82M	1.79	767,239 shs	845,887 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+10.48%	+6.94%	+18.40%	+11.48%	+72.26%
OVID Ovid Therapeutics	+3.17%	+11.83%	+26.84%	+20.08%	+211.70%
TLRY Tilray Brands	+8.05%	+3.21%	+14.18%	-11.54%	-54.43%
UNCY Unicycive Therapeutics	-0.89%	+3.53%	+2.39%	-26.87%	+37.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	2.40	Hold	$20.25	26.40% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.71	95.03% Upside
TLRY Tilray Brands	2.50	Moderate Buy	$11.00	127.74% Upside
UNCY Unicycive Therapeutics	2.43	Hold	$18.25	227.06% Upside

Current Analyst Ratings Breakdown

Latest UNCY, TLRY, OVID, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00 ➝ $25.00
8/12/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00 ➝ $20.00
8/7/2026	TLRY Tilray Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/31/2026	TLRY Tilray Brands	TD Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	CTNM Contineum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	TLRY Tilray Brands	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	12.05	N/A	N/A	$6.37 per share	2.51
OVID Ovid Therapeutics	$7.25M	78.93	N/A	N/A	$1.07 per share	2.74
TLRY Tilray Brands	$915.45M	0.72	N/A	N/A	$13.68 per share	0.35
UNCY Unicycive Therapeutics	$680K	228.53	N/A	N/A	$1.91 per share	2.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	N/A
TLRY Tilray Brands	-$121.40M	-$1.08	N/A	N/A	N/A	-13.11%	-7.76%	-5.59%	10/8/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	2.58	N/A	N/A	-91.50%	-61.47%	N/A

Latest UNCY, TLRY, OVID, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A
7/28/2026	Q4 2026	TLRY Tilray Brands	-$0.0120	-$0.43	-$0.4180	-$0.43	$246.30 million	$281.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	37.17	37.17
OVID Ovid Therapeutics	0.05	12.39	12.39
TLRY Tilray Brands	0.22	2.21	1.37
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
OVID Ovid Therapeutics	72.24%
TLRY Tilray Brands	9.35%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	7.90%
OVID Ovid Therapeutics	7.00%
TLRY Tilray Brands	0.84%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
OVID Ovid Therapeutics	60	195.30 million	181.63 million	Optionable
TLRY Tilray Brands	3,595	136.20 million	135.06 million	Optionable
UNCY Unicycive Therapeutics	9	27.85 million	26.18 million	Not Optionable

UNCY, TLRY, OVID, and CTNM Headlines

Recent News About These Companies

Noble Financial Issues Positive Outlook for UNCY Earnings

August 17 at 1:13 AM | americanbankingnews.com

HC Wainwright Issues Negative Forecast for UNCY Earnings

August 17 at 1:12 AM | americanbankingnews.com

Research Analysts Set Expectations for UNCY Q3 Earnings

August 17 at 1:11 AM | marketbeat.com

Noble Financial Has Positive Forecast for UNCY Q3 Earnings

August 17 at 1:11 AM | marketbeat.com

Noble Financial Analysts Lower Earnings Estimates for UNCY

August 16, 2026 | americanbankingnews.com

Unicycive Therapeutics (NASDAQ:UNCY) Raised to Hold at Wall Street Zen

August 15, 2026 | americanbankingnews.com

Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

August 14, 2026 | marketbeat.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages

August 13, 2026 | marketbeat.com

Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

August 13, 2026 | msn.com

Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results

August 12, 2026 | marketbeat.com

Unicycive Therapeutics Reports FDA Facility Inspection Assigned for OLC Manufacturing Vendor, Plans NDA Resubmission After Successful Inspection

August 12, 2026 | quiverquant.comQ

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026 | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Strong Sell Rating by Zacks Research

July 23, 2026 | marketbeat.com

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

July 16, 2026 | theglobeandmail.com

UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

July 13, 2026 | globenewswire.com

Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)

July 10, 2026 | theglobeandmail.com

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

July 10, 2026 | globenewswire.com

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

July 8, 2026 | businesswire.com

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...

July 8, 2026 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UNCY, TLRY, OVID, and CTNM Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$16.02 +1.52 (+10.48%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$15.88 -0.14 (-0.87%)

As of 08/19/2026 07:30 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Ovid Therapeutics NASDAQ:OVID

$2.93 +0.09 (+3.17%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$2.81 -0.12 (-4.23%)

As of 04:00 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Tilray Brands NASDAQ:TLRY

$4.83 +0.36 (+8.05%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$4.78 -0.05 (-1.14%)

As of 04:01 AM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

Unicycive Therapeutics NASDAQ:UNCY

$5.58 -0.05 (-0.89%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$5.57 -0.01 (-0.20%)

As of 08/19/2026 07:58 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UNCY, TLRY, OVID, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UNCY, TLRY, OVID, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UNCY, TLRY, OVID, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UNCY, TLRY, OVID, and CTNM Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

Ovid Therapeutics NASDAQ:OVID

Tilray Brands NASDAQ:TLRY

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UNCY, TLRY, OVID, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UNCY, TLRY, OVID, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UNCY, TLRY, OVID, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UNCY, TLRY, OVID, and CTNM Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

Ovid Therapeutics NASDAQ:OVID

Tilray Brands NASDAQ:TLRY

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools